In Minneapolis, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a biopharmaceutical company targeting preeclampsia, fetal growth restriction, and acute ischemic stroke, disclosed that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will engage in investor conferences in New York City. They will attend the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, as speakers.